EP Wealth Advisors LLC Invests $641,000 in Guardant Health, Inc. $GH

EP Wealth Advisors LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 4,274 shares of the company’s stock, valued at approximately $641,000.

Other large investors have also added to or reduced their stakes in the company. Orbimed Advisors LLC bought a new stake in Guardant Health during the 1st quarter worth approximately $40,199,000. World Investment Advisors acquired a new position in Guardant Health in the 4th quarter valued at approximately $1,664,000. GSA Capital Partners LLP bought a new position in shares of Guardant Health during the second quarter valued at $1,772,000. Ninepoint Partners LP bought a new position in shares of Guardant Health during the second quarter valued at $2,853,000. Finally, SWS Partners bought a new position in shares of Guardant Health during the second quarter valued at $11,190,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Down 4.4%

Shares of GH opened at $163.18 on Tuesday. The firm’s fifty day simple moving average is $154.58 and its two-hundred day simple moving average is $119.07. Guardant Health, Inc. has a 12 month low of $53.40 and a 12 month high of $176.58. The stock has a market capitalization of $21.90 billion, a P/E ratio of -46.76 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. The business’s revenue was up 44.3% on a year-over-year basis. During the same period last year, the business posted ($0.44) earnings per share. As a group, research analysts predict that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, insider Chris Freeman sold 63,605 shares of Guardant Health stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the sale, the insider directly owned 65,374 shares in the company, valued at approximately $11,086,122.92. The trade was a 49.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Amirali Talasaz sold 37,500 shares of Guardant Health stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $169.16, for a total value of $6,343,500.00. Following the completion of the sale, the chief executive officer owned 37,500 shares of the company’s stock, valued at approximately $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 559,318 shares of company stock valued at $83,882,733 over the last ninety days. Insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on GH shares. UBS Group set a $150.00 price objective on shares of Guardant Health in a research note on Wednesday, June 24th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Guardant Health in a research report on Friday, July 31st. Stifel Nicolaus lifted their target price on Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, July 31st. BTIG Research upped their price target on Guardant Health from $190.00 to $195.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Citigroup increased their price target on Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.